CADTH Canadian Drug Expert Committee recommendation : indication : management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activityOcrelizumab (Ocrevus-Hoffmann-La Roche Limited)
The CADTH Canadian Drug Expert Committee recommends that crelizumab be reimbursed for the management of adult patients with early PPMS as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity, if the following criteria and conditions are met. Clinical criteria: therapy may be initiated if the patient: is between 18 and 55 years old; has a confirmed diagnosis of PPMS (based on McDonald criteria 2010), with an Expanded Disability Status Scale (EDSS) score between 3.0 and 6.5; a score of at least 2.0 on the Functional Systems scale for the pyramidal system due to lower extremity findings; and a disease duration of less than 15 years for those with an EDSS greater than 5.0 or less than 10 years for those with an EDSS of 5.0 or less. Treatment should be discontinued for patients with an EDSS score of equal to or greater than 7.0..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
April 30, 2018 |
|---|---|
| Erschienen: |
Ottawa (ON): CADTH ; April 30, 2018 |
| Ausgabe: |
Version: 1.0. |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
"Final.". - Description based on online resource; title from PDF title page (viewed February 27, 2019) |
|---|
| Umfang: |
1 online resource (1 PDF file (8 pages)). |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1773195131 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1773195131 | ||
| 003 | DE-627 | ||
| 005 | 20230428012025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2018 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1773195131 | ||
| 035 | |a (DE-599)KEP068698011 | ||
| 035 | |a (NCBI)1740672 | ||
| 035 | |a (EBP)068698011 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 110 | 2 | |a CADTH Canadian Drug Expert Committee, |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CADTH Canadian Drug Expert Committee recommendation |b indication : management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activityOcrelizumab (Ocrevus-Hoffmann-La Roche Limited) |
| 250 | |a Version: 1.0. | ||
| 264 | 1 | |a Ottawa (ON) |b CADTH |c April 30, 2018 | |
| 300 | |a 1 online resource (1 PDF file (8 pages)). | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH common drug review | |
| 500 | |a "Final.". - Description based on online resource; title from PDF title page (viewed February 27, 2019) | ||
| 520 | |a The CADTH Canadian Drug Expert Committee recommends that crelizumab be reimbursed for the management of adult patients with early PPMS as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity, if the following criteria and conditions are met. Clinical criteria: therapy may be initiated if the patient: is between 18 and 55 years old; has a confirmed diagnosis of PPMS (based on McDonald criteria 2010), with an Expanded Disability Status Scale (EDSS) score between 3.0 and 6.5; a score of at least 2.0 on the Functional Systems scale for the pyramidal system due to lower extremity findings; and a disease duration of less than 15 years for those with an EDSS greater than 5.0 or less than 10 years for those with an EDSS of 5.0 or less. Treatment should be discontinued for patients with an EDSS score of equal to or greater than 7.0. | ||
| 650 | 2 | |a Multiple Sclerosis |x drug therapy |0 https://id.nlm.nih.gov/mesh/D009103Q000188 | |
| 650 | 2 | |a Antibodies, Monoclonal |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D000911Q000627 | |
| 650 | 2 | |a Antibodies, Monoclonal |x economics |0 https://id.nlm.nih.gov/mesh/D000911Q000191 | |
| 650 | 2 | |a Immunologic Factors |x economics |0 https://id.nlm.nih.gov/mesh/D007155Q000191 | |
| 650 | 2 | |a Insurance, Health, Reimbursement |x economics |0 https://id.nlm.nih.gov/mesh/D007349Q000191 | |
| 650 | 2 | |a Insurance, Pharmaceutical Services |x economics |0 https://id.nlm.nih.gov/mesh/D007356Q000191 | |
| 650 | 2 | |a Drug Costs |0 https://id.nlm.nih.gov/mesh/D016527 | |
| 650 | 2 | |a Cost-Benefit Analysis |0 https://id.nlm.nih.gov/mesh/D003362 | |
| 651 | 2 | |a Canada |0 https://id.nlm.nih.gov/mesh/D002170 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK532699/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994091918 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994018196 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 399979478X |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995684300 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987685034 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987770872 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK532699/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK532699/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK532699/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK532699/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK532699/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||